ASANTE (6073) AI Stock Analysis

• Market Cap: ¥15.81B
• Dividend Yield: 3.83%
• Average Volume (3M): 21.68K
• Price to Earnings (P/E): 31.9
• Beta (1Y): 0.32
• Revenue Growth: 1.80%
• EPS Growth: -7.69%
• Country: JP
• Employees: 998
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Residential Construction
• EPS (TTM): 33.81
• Shares Outstanding: 12,348,500
• 10 Day Avg. Volume: 12,050
• 30 Day Avg. Volume: 21,680
• PEG Ratio: 0.72
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 16.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ¥1,744.00 ▲(7.46% Upside)

ASANTE's overall stock score is driven primarily by its stable financial performance and strong cash flow generation. However, the stock's technical indicators suggest caution due to potential bearish momentum. Additionally, the high P/E ratio indicates the stock may be overvalued, which could limit upside potential. The dividend yield provides some support for income investors.

ASANTE Business Overview & Revenue Model

Company Description

ASANTE (6073) is a biotechnology company focused on developing and commercializing innovative diagnostic solutions and therapies for various health conditions. The company operates in the healthcare sector, specializing in the production of advanced medical devices and diagnostic tools that aim to improve patient outcomes through early detection and monitoring of diseases. ASANTE's core products include cutting-edge diagnostic kits and monitoring systems that cater to both clinical and home-use settings.

How the Company Makes Money

ASANTE generates revenue primarily through the sale of its diagnostic products and medical devices to healthcare providers, hospitals, and direct consumers. The company has established key revenue streams from both domestic and international sales, leveraging partnerships with distributors and healthcare organizations to expand its market reach. Additionally, ASANTE may engage in research collaborations and licensing agreements with pharmaceutical companies, which further contribute to its earnings. The company's focus on innovation and adherence to regulatory standards positions it competitively within the biotechnology market, allowing for potential growth in revenue as it introduces new products and enters emerging markets.

ASANTE Financial Statement Overview

Summary

ASANTE demonstrates stable financial performance with strong operational efficiency and a robust balance sheet. The company shows modest revenue growth and maintains low leverage, which reduces financial risk. While the net profit margin is relatively low, the strong cash flow generation and healthy capital structure position ASANTE well for future growth and stability.

Income Statement

ASANTE's income statement shows a stable performance with a gross profit margin of 69.2% and a net profit margin of 4.9% for 2025. The revenue growth rate from 2024 to 2025 is 2.4%, indicating modest growth. EBIT and EBITDA margins are 8.7% and 9.4%, respectively, reflecting solid operational efficiency. However, the net profit margin is relatively low, suggesting room for improvement in cost management.

Balance Sheet

The balance sheet is strong with a debt-to-equity ratio of 0.24, indicating low leverage and financial stability. The return on equity (ROE) is 7.1%, showing a reasonable return for shareholders. The equity ratio stands at 67.9%, highlighting a robust capital structure with a high proportion of equity financing. Overall, the company maintains a healthy balance sheet with low financial risk.

Cash Flow

ASANTE's cash flow statement reveals a significant free cash flow growth rate of 217.2% from 2024 to 2025, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.63, suggesting efficient cash conversion. However, the free cash flow to net income ratio is 1.53, which while strong, indicates that not all net income translates into free cash flow due to capital expenditures.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.98B	14.02B	13.69B	14.14B	13.70B	13.87B
Gross Profit	9.60B	9.71B	9.44B	9.73B	9.42B	9.71B
EBITDA	1.03B	1.31B	1.12B	1.54B	1.27B	1.91B
Net Income	520.16M	687.90M	541.41M	875.82M	579.15M	1.06B
Balance Sheet
Total Assets	14.90B	14.35B	16.13B	14.46B	14.07B	14.43B
Cash, Cash Equivalents and Short-Term Investments	7.16B	7.11B	8.72B	6.66B	6.66B	6.68B
Total Debt	2.41B	2.36B	2.36B	424.42M	482.31M	648.13M
Total Liabilities	5.11B	4.60B	4.38B	2.73B	2.52B	2.76B
Stockholders Equity	9.79B	9.74B	11.74B	11.73B	11.56B	11.67B
Cash Flow
Free Cash Flow	0.00	1.05B	330.81M	1.16B	831.55M	865.51M
Operating Cash Flow	0.00	1.12B	448.10M	1.20B	869.55M	929.51M
Investing Cash Flow	0.00	-61.50M	384.61M	-449.51M	-40.49M	-309.81M
Financing Cash Flow	0.00	-2.67B	1.23B	-754.54M	-847.50M	-2.99B

ASANTE Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1623.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6073, the sentiment is Negative. The current price of 1623 is below the 20-day moving average (MA) of 1629.85, below the 50-day MA of 1646.30, and above the 200-day MA of 1603.22, indicating a neutral trend. The MACD of -6.08 indicates Positive momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 18.06 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6073.

ASANTE Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8917	74 Outperform	¥15.45B	5.87	―	3.86%	5.76%	99.51%
1430	68 Neutral	¥11.19B	6.98	―	4.51%	41.95%	35.36%
6073	64 Neutral	¥15.81B	31.86	5.03%	3.83%	1.80%	-7.69%
1420	64 Neutral	¥7.83B	7.07	―	3.58%	6.24%	39.37%
1873	62 Neutral	¥12.04B	34.20	―	3.70%	―	―
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
8904	54 Neutral	¥11.64B	18.43	―	4.63%	-2.47%	7.77%

ASANTE Corporate Events

Asante Announces Director Change to Boost Sales Division

Asante, Inc. announced a change in its board of directors, effective October 1, 2025. Tetsuji Hamazato will assume the role of Director and Head of Sales Division, expanding his responsibilities to include the Corporate Sales Department. This strategic move is expected to enhance the company’s sales operations and strengthen its market position.

The most recent analyst rating on (JP:6073) stock is a Buy with a Yen1819.00 price target. To see the full list of analyst forecasts on ASANTE stock, see the JP:6073 Stock Forecast page.

Asante Completes Treasury Shares Disposal for Stock Compensation

Asante, Inc. has completed the payment procedures for the disposal of 10,500 treasury shares as restricted stock compensation, a decision made during their Board of Directors meeting on July 18, 2025. This move, involving a total value of 16,957,500 yen, is targeted at the company’s directors, excluding outside directors, and reflects Asante’s strategic approach to incentivize its leadership team.

Asante, Inc. Reports Decline in Q1 2025 Financial Results but Projects Recovery

Asante, Inc. reported a decline in its financial performance for the first quarter ended June 30, 2025, with net sales slightly decreasing by 1.1% and significant drops in operating income, ordinary income, and net income attributable to owners of the parent. Despite these declines, the company maintains a stable financial position with a high shareholders’ equity ratio. The forecast for the fiscal year ending March 2026 anticipates growth in net sales and net income, suggesting a potential recovery and positive outlook for stakeholders.